T1	intervention 75 111	high-dose thiotepa, cyclophosphamide
T3	total-participants 435 438	308
T4	eligibility 439 531	patients with histologically proven metastatic breast cancer responding to induction therapy
T5	total-participants 715 718	179
T6	intervention-participants 845 847	88
T7	control 853 873	no further treatment
T8	control-participants 877 879	91
T9	outcome 949 960	toxic death
T10	iv-bin-abs 945 948	One
T11	outcome 1020 1045	response rate at 3 months
T12	iv-bin-percent 1085 1090	82.7%
T13	iv-bin-percent 1092 1097	25.3%
T14	outcome 1098 1120	complete response (CR)
T15	cv-bin-percent 1129 1134	59.2%
T16	cv-bin-percent 1136 1141	14.1%
T17	outcome 1190 1200	Median DFS
T18	iv-cont-median 1205 1207	11
T19	cv-cont-median 1212 1222	6.6 months
T20	outcome 1310 1318	survival
T21	iv-bin-percent 1331 1335	33.6
T22	cv-bin-percent 1343 1348	27.3%
T23	outcome 1349 1362	OS at 3 years
T24	iv-cont-median 1375 1379	22.9
T25	cv-cont-median 1387 1398	22.3 months
T26	outcome 1399 1421	median time to relapse
